Characterization of non-peptide bradykinin B2 receptor agonist (FR 190997) and antagonist (FR 173657)

被引:21
作者
Gobeil, F
Montagne, M
Inamura, N
Regoli, D
机构
[1] Univ Sherbrooke, Sch Med, Dept Pharmacol, Sherbrooke, PQ J1H 5N4, Canada
[2] Fujisawa Pharmaceut Co Ltd, Osaka 532, Japan
来源
IMMUNOPHARMACOLOGY | 1999年 / 43卷 / 2-3期
关键词
FR; 190997; 173657; B-2; receptor; bioassays; rabbit; guinea pig; rat;
D O I
10.1016/S0162-3109(99)00129-0
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
pharmacologic parameters for a novel non-peptide bradykinin (BK)-B-2 receptor agonist, 8-[2,6-dichloro-3-[ N-[( E)-4-N-methylcarbamoylcinnamidoacetyl]-N-methylamino] benzyloxy]-2-methyl-4-(2-pyridylmethoxy)quinoline (FR 190997) (PEC50, ED50 values) and for the antagonist ( E)-3-(6-acetamido-3-pyridyl)-[ N-[2,4-dichloro-3-[(2-methyl-8-quinolinyl) oxymethyl] phenyl]-N-methylaminocarbonylmethyl] acrylamide (FR 173657) (pIC(50), ID50 values) were measured using conventional contractile B-2 receptor bioassays from rabbit, guinea pig and rat tissues and by mean of animal blood pressure models performed on anesthetized animals in the same species. In vitro assays ton the rabbit jugular vein and the guinea pig ileum) demonstrated that both the onset and duration of action of FR 190997 are prolonged compared to BK. These in vitro effects of FR 190997 strongly desensitized upon repeated tissue applications, Similar pEC(50) values (7.7) were measured on the rabbit and the guinea pig tissues. In vivo, when injected intraarterially, FR 190997 produced hypotensive responses in rabbits and guinea pigs with EDS, values of 3.7 +/- 0.5 and 8.9 +/- 3.6 nmol/kg, respectively. Both the contractile and the hypotensive effects of FR 190997 were abolished by pretreating tissues (1 mu M) or animals (0.1-0.5 mu mol/kg) with D-Arg-[Hyp(3),Thi(5),D-TiC7,OiC(8)]BK (HOE 140) or FR 173657. FR 173657 (pIC(50) approximate to 8.40), as well as other known antagonists (e.g., HOE 140, DArg-[Hyp(3),D-Phe(7),Leu(8)]BK), inhibited the in vitro myotropic effects of BK on the rabbit, guinea pig and rat tissues. FR 173657 also abrogated the in vivo hypotensive responses elicited by BK in the rabbit (ID50 57 +/- 9 nmol/kg), the guinea pig (ID50 215 +/- 56 nmol/kg) and the rat (ID50 187 +/- 50 nmol/kg. The in vivo duration of action of FR 173657 was significantly lower in the rabbit (approximate to 20 min) than in the guinea pig and the rat (> 90 min). It is concluded that the non-peptides FR 190997 and FR 173657 enable efficient activation and antagonism of rabbit and guinea pig B-2 receptors. These non-peptide molecules represent a marked progress in medicinal chemistry and may be useful to define the role played by the kallikrein/kinin system in vivo, (C) 1999 Elsevier Science B.V. All Fights reserved.
引用
收藏
页码:179 / 185
页数:7
相关论文
共 12 条
[1]   Nonpeptide mimic of Bradykinin with long-acting properties at the Bradykinin B-2 receptor [J].
Aramori, I ;
Zenkoh, J ;
Morikawa, N ;
Asano, M ;
Hatori, C ;
Sawai, H ;
Kayakiri, H ;
Satoh, S ;
Inoue, T ;
Abe, Y ;
Sawada, Y ;
Mizutani, T ;
Inamura, N ;
Nakahara, K ;
Kojo, H ;
Oku, T ;
Notsu, Y .
MOLECULAR PHARMACOLOGY, 1997, 52 (01) :16-20
[2]   The identification of an orally active, nonpeptide bradykinin B-2 receptor antagonist, FR173657 [J].
Asano, M ;
Inamura, N ;
Hatori, C ;
Sawai, H ;
Fujiwara, T ;
Katayama, A ;
Kayakiri, H ;
Satoh, S ;
Abe, Y ;
Inoue, T ;
Sawada, Y ;
Nakahara, K ;
Oku, T ;
Okuhara, M .
BRITISH JOURNAL OF PHARMACOLOGY, 1997, 120 (04) :617-624
[3]   In vitro and in vivo characterization of bradykinin B-2 receptors in the rabbit and the guinea pig [J].
Gobeil, F ;
Filteau, C ;
Pheng, LH ;
Jukic, D ;
NguyenLe, XK ;
Regoli, D .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1996, 74 (02) :137-144
[4]  
HOCK FJ, 1991, BRIT J PHARMACOL, V102, P769, DOI 10.1111/j.1476-5381.1991.tb12248.x
[5]  
JENKINSON DH, 1995, PHARMACOL REV, V47, P255
[6]   BRADYKININ RECEPTOR TYPES AND B-2 SUBTYPES [J].
REGOLI, D ;
GOBEIL, F ;
NGUYEN, QT ;
JUKIC, D ;
SEOANE, PR ;
SALVINO, JM ;
SAWUTZ, DG .
LIFE SCIENCES, 1994, 55 (10) :735-749
[7]   PHARMACOLOGICAL CHARACTERIZATION OF A NEW HIGHLY POTENT B2-RECEPTOR ANTAGONIST (HOE 140-D-ARG-[HYP3,THI5,D-TIC7,OIC8]BRADYKININ) [J].
RHALEB, NE ;
ROUISSI, N ;
JUKIC, D ;
REGOLI, D ;
HENKE, S ;
BREIPOHL, G ;
KNOLLE, J .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1992, 210 (02) :115-120
[8]   FR 173657: A new, potent, nonpeptide kinin B-2 receptor antagonist - An in vitro study [J].
Rizzi, A ;
Gobeil, F ;
Calo, G ;
Inamura, N ;
Regoli, D .
HYPERTENSION, 1997, 29 (04) :951-956
[9]   BRADYKININ ANTAGONISTS - DEVELOPMENT AND APPLICATIONS [J].
STEWART, JM .
BIOPOLYMERS, 1995, 37 (02) :143-155
[10]   Oral activity of peptide bradykinin antagonists following intragastric administration in the rat [J].
Whalley, ET ;
Hanson, WL ;
Stewart, JM ;
Gera, L .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1997, 75 (06) :629-632